RecruitingNot ApplicableNCT05999006

Safety and Feasibility of the ELIOS System in POAG Patients

A Prospective, Multicenter, Clinical Trial Designed to Evaluate the Safety and Feasibility of the ELIOS System to Reduce Intraocular Pressure in Patients With Primary Open-Angle Glaucoma as a Standalone Procedure


Sponsor

Elios Vision, Inc.

Enrollment

65 participants

Start Date

Oct 18, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Evaluation of the safety and effectiveness of the ELIOS System procedure to reduce intraocular pressure (IOP) in adult subjects with mild to moderate primary open-angle glaucoma (POAG)


Eligibility

Min Age: 45 Years

Inclusion Criteria5

  • Diagnosis of mild to moderate POAG
  • Medicated IOP of \<=24 mmHg
  • Shaffer angle grade of III or IV
  • CD ratio \<=0.8
  • At least 45 years old

Exclusion Criteria4

  • Closed-angle and secondary glaucomas
  • Prior incisional glaucoma surgery, intraocular surgery, or corneal surgery
  • Cannot undergo medication washout in the study eye
  • Diagnosis of degenerative visual disorders Non-study eye with BCVA worse than 20/80 Known corticosteroid responder Pregnant or nursing women; or women of childbearing potential not using medically acceptable birth control

Interventions

DEVICEELIOS Procedure

Treatment with the ELIOS System


Locations(5)

Elios Vision Clinical Site

Glendale, Arizona, United States

Elios Vision Clinical Site

Largo, Florida, United States

Elios Vision Clinical Site

Rock Island, Illinois, United States

Elios Vision Clinical Site

Oklahoma City, Oklahoma, United States

Elios Vision Clinical Site

Kenosha, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05999006


Related Trials